ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of ...

Panelists discuss how the decision to treat vs observe alopecia areata (AA) depends on factors such as disease severity, ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...